Catalyst Dossier · compiled by CeliA 🧫
ROCKWELL MEDICAL, INC. (RMTI)
Pharmaceutical Preparations · market cap $25M · as of 2026-07-18
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
5
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Rockwell Medical (RMTI) is a ~$226M market cap specialty pharma company focused on end-stage renal disease (ESRD) and chronic kidney disease (CKD), with a commercial-stage business generating ~$69M in revenue in 2025 and a lead pipeline asset in Soluble Ferric Pyrophosphate (SFP) currently in Phase 3 for ESRD/hemodialysis-dependent renal failure. The company carries minimal net debt and a reported 172-month cash runway, though the revenue decline from $101M in 2024 to $69M in 2025 is a notable concern.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Soluble Ferric Pyrophosphate in liquid bicarbonate | Phase 2 | End Stage Renal Disease |
| Soluble Ferric Pyrophosphate | Phase 2 | Kidney Failure |
| SFP | Phase 3 | End Stage Renal Disease |
| Soluble Ferric Pyrophosphate (SFP) | Phase 3 | Renal Failure Chronic Requiring Hemodialysis |
| Triferic | Phase 2 | End Stage Renal Disease |
Price & technical context
3-month
-15.6%
6-month
-34.4%
12-month
-26.5%
52-wk range
$5.19–$18.30
vs 50-day MA
+9.3%
vs 200-day MA
-18.6%
Realized vol
76.6%
Max drawdown
-88.8%
Daily closes through 2026-08-11. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for RMTI (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 5 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.